SCHEMBL1807211

SCHEMBL1807211

Cc1[nH]nc(C(=O)N2CCC(Oc3ccc(Cl)cc3)CC2)c1Cl

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 1/20 0.54
PROKR1 Q8TCW9 1/20 0.54
CNR1 P21554 6/20 0.48
GRIN2D O15399 1/20 0.45
GRIN3B O60391 1/20 0.45
GRIN1 Q05586 1/20 0.45
GRIN2A Q12879 1/20 0.45
GRIN2B Q13224 1/20 0.45
GRIN2C Q14957 1/20 0.45
GRIN3A Q8TCU5 1/20 0.45
EPHX2 P34913 2/20 0.44
KCNH2 Q12809 2/20 0.44
MCHR1 Q99705 2/20 0.44
HRH1 P35367 1/20 0.44
CCR3 P51677 1/20 0.44
KMT2A Q03164 1/20 0.43
HRH3 Q9Y5N1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1806251 0.84 FPR2 (0.60) FPR2PROKR1CNR1GRIN2DGRIN3B
SCHEMBL1807938 0.81 EIF4A3 (0.56) CNR1EPHX2KCNH2HRH1CCR3
SCHEMBL1808575 0.81 RBP4 (0.59) CNR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1810866 0.81 RBP4 (0.59) FPR2PROKR1CNR1GRIN2DGRIN3B
SCHEMBL12168202 0.80 CNR1 (0.51) FPR2PROKR1CNR1GRIN2DGRIN3B
SCHEMBL12168195 0.80 FPR2 (0.49) FPR2PROKR1CNR1GRIN2DGRIN3B
SCHEMBL1809156 0.80 GRIN2D (0.50) FPR2PROKR1GRIN2DGRIN3BGRIN1
SCHEMBL1813014 0.79 NPC1 (0.47) CNR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL12188570 0.78 RBP4 (0.52) CNR1GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL1808765 0.78 RBP4 (0.56) CNR1GRIN2DGRIN3BGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9051296-B2 Aryl carboxamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-06-09 US claimed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 US claimed
WO-2011058766-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2011-05-19 WO claimed
US-9051296-B2 Aryl carboxamide derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-06-09 US disclosed
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-09-13 US disclosed
WO-2011058766-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232052-A1 ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS SCN1B, SCN1A, SCN2B FPR2 419/4885PROKR1 3885/4885CNR1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.